Company Milestone

August 2021Launch of first polygenic breast cancer risk assessment score validated for women of all ancestries.
June 2021Myriad Genetics shares new data at ASCO validating personalized breast cancer risk assessments for women of all ancestries.
March 2021Myriad joins forces with Intermountain Precision Genomics for a comprehensive offering of germline and somatic tumor testing services.
August 2020Paul J. Diaz appointed President and Chief Executive Officer of Myriad Genetics.
December 2018Myriad validates first ever polygenic score to predict breast cancer risk in women of Hispanic ancestry.
July 2018Myriad acquires Counsyl and enters the reproductive genetic testing market.
May 2018GeneSight® data from a landmark randomized control trial is presented at the American Psychiatric Association annual meeting.
April 2018Myriad launches new corporate Go Green sustainably initiative.
January 2018Myriad receives FDA approval for BRACAnalysis CDx® as a companion diagnostic for Lynparza™ in patients with metastatic breast cancer.
September 2017Myriad launches riskScore®, a polygenic breast cancer risk assessment tool.
May 2017Medicare Coverage of Prolaris® expands to include men with favorable-intermediate prostate cancer.
March 2017EndoPredict® test is launched in the United States.
August 2016Myriad acquires Assurex Health and the GeneSight® genetic test.
May 2016Myriad acquires Sividon Diagnostics, a leading breast cancer prognostic company.
October 2015Myriad and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer.
October 2015Myriad receives Medicare coverage of Prolaris® for prostate cancer patients.
September 2015Myriad unveils its new logo, the first update since the Company’s founding in 1991.
January 2015Myriad receives European CE Marking approval for its Tumor BRACAnalysis CDx test for use as a companion diagnostic to predict responders to PARP inhibitors such as Lynparza (olaparib).
December 2014Myriad receives FDA approval for its BRACAnalysis CDx® test to identify ovarian cancer patients who may benefit from the PARP inhibitor Lynparza (olaparib).
November 2014Myriad and TESARO announce an expanded companion diagnostic agreement during the second quarter to use Myriad’s myChoice® HRD test in clinical studies in support of niraparib, TESARO’s novel PARP inhibitor
November 2014Myriad and AbbVie sign expanded agreement for Tumor BRACAnalysis CDx and veliparib.
October 2014Myriad establishes Tumor BRACAnalyis CDx laboratory in Europe to help identify patients with BRCA mutations who many benefit from treatment with PARP inhibitors such as AstraZeneca’s olaparib.
October 2014Myriad receives draft Medicare coverage for Prolaris®, a revolutionary test for prostate cancer.
April 2014Myriad submits a premarket approval application to the FDA for BRACAnalysis CDx® as a companion diagnostic with a PARP inhibitor. (BRACAnalysis CDx is one of the first laboratory developed tests submitted for FDA premarket approval).
February 2014Myriad acquires of California-based Crescendo Biosciences, Inc. and diversifies into the autoimmune market.
January 2014Myriad licenses EndoPredict®, a second generation prognostic test kit for patients diagnosed with breast cancer.
November 2013Myriad launches the Myriad myPath® Melanoma diagnostic test to differentiate benign skin lesions from malignant melanoma.
October 2013Myriad launches the Myriad myPlan® Lung Cancer prognostic test for patients with lung cancer.
September 2013Myriad launches Myriad MyRisk Hereditary Cancer, a 25-gene panel test for eight major cancers.
February 2013The one-millionth patient is tested with BRACAnalysis® test.
February 2012Myriad announces opening of European laboratory in Munich, Germany.
February 2012Clinical study shows Prolaris® to predict prostate cancer aggressiveness and patient risk of recurrence.
June 2011Myriad acquires Texas-based Rules Based Medicine and forms Myriad RBM®, a wholly owned subsidiary.
2011Myriad enters into three companion diagnostic collaborations for PARP inhibitors.
December 2010Myriad launches PANEXIA®, a predictive test for hereditary pancreatic cancer.
November 2010Crescendo Bioscience, Inc. announces the launch of Vectra® DA, the first multi-biomarker blood test that measures rheumatoid arthritis disease activity.
March 2010Myriad launched Prolaris®, the first prognostic test to predict prostate cancer survival.
July 2009Myriad announces the spinoff to shareholders of its pharmaceutical business.
December 2008Myriad launches PREZEON®, a genetic test to assess the status of the PTEN gene.
January 2008Myriad launches BRACAnalysis® for the women’s health preventative care market, significantly expanding access to genetic cancer testing.
August 2007Myriad announces third Phase 2 clinical trial for Azixa, a molecular disruption agent.
August 2006Myriad launches BART, a large rearrangement test for high-risk breast cancer patients.
May 2005Myriad announces results of a Phase 2 Alzheimer’s drug clinical trial.
December 2004Myriad tests 100,000 women for breast cancer predisposition.
June 2004Myriad submits investigational new drug applications on two cancer drugs to FDA.
February 2003Myriad announces the discovery of major depression gene in collaboration with Abbott Laboratories.
May 2002Myriad launches COLARIS AP®, a genetic test for FAP colon cancer syndrome.
November 2001Myriad launches MELARIS®, a test for melanoma.

Myriad publishes in Cell, the discovery of a novel HIV cellular process.

February 2001Myriad announces complete map of the rice genome.
September 2000Myriad launches COLARIS®, a genetic test for hereditary colorectal and uterine cancer.
April 1999Myriad incorporates Myriad Pharmaceuticals to develop novel therapies.
January 1998Myriad launches ProNet, a proprietary protein-interaction technology.
March 1997Myriad announces the discovery of the PTEN gene that is associated with a large number of cancers.
November 1996Myriad launches BRACAnalysis®, the first full length gene sequencing test for a major, common disease, for the oncology market.
December 1995Myriad announces the discovery of the BRCA 2 gene that is associated with hereditary breast and ovarian cancer.
October 1995Myriad becomes a public company and is traded on NASDAQ under the ticker: MYGN.
September 1994Myriad scientists publishes in Science the discovery of the BRCA 1 gene that is associated with hereditary breast and ovarian cancer.
Fall 1993Myriad announces the discovery of the P16 gene that is associated with hereditary melanoma.
May 1991Myriad Genetics, Inc. is founded, making it one of the first genomics companies in history.